Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation
Kendall C. Shultes(VA Tennessee Valley Healthcare System), Sean DeFrates(Northwestern Memorial Hospital), Christopher J. Arp(Carolinas Medical Center), Kathryn Trinkaus(Washington University in St. Louis), Keith Stockerl‐Goldstein(City Of Hope National Medical Center)
Cited by 6
Related Papers
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
|Blood|2003|407
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
|JAMA Oncology|2021|185
Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated
|Biology of Blood and Marrow Transplantation|2016|164